Enliven Therapeutics, Inc.

NASDAQ:ELVN

Biotechnology

Healthcare
$46.41 -0.27%

-$0.12 today

Market cap
$3.42B
Beta
0.40
P/E (TTM)
-28.4
EPS (TTM)
-$1.57
52W Low $14.79High $48.53

Volume 0.99M

Average 1.35M

Balance Sheet

Inspect the capital base behind the business.

Assets

$476.17M

FY 2025 · Annual

+46.2% YoY

Liabilities

$16.68M

FY 2025 · Annual

+4.8% YoY

Equity

$459.60M

FY 2025 · Annual

+48.3% YoY

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents110.02M75.54M100.14M124.12M98.9M
Short-term Investments00153.01M189.32M363.73M
Net Receivables00000
Inventory00000
Other Current Assets02.22M10.05M4.69M12.26M
Total Current Assets110.67M77.75M266.15M318.13M474.88M
Property, Plant & Equipment (Net)954K1.52M1.06M458K417K
Goodwill00000
Intangible Assets00000
Long-term Investments054K000
Tax Assets00000
Other Non-current Assets1.71M3.98M4.65M7.18M873K
Total Non-current Assets2.66M5.55M5.72M7.63M1.29M
Total Assets113.33M83.3M271.87M325.76M476.17M
Account Payables2.52M3.44M532K1.34M2.16M
Short-term Debt00000
Tax Payables00000
Deferred Revenue05.51M000
Other Current Liabilities233K320K10.36M204K4.65M
Total Current Liabilities5.75M9.72M25.89M15.92M16.57M
Long-term Debt00000
Deferred Tax Liabilities0000108K
Deferred Revenue (Non-current)00000
Other Non-current Liabilities714K150.41M67K00
Total Non-current Liabilities714K150.41M67K0108K
Total Liabilities6.47M160.12M25.96M15.92M16.68M
Common Stock1K1K41K49K59K
Retained Earnings(45.2M)(82.86M)(154.45M)(243.47M)(347.17M)
Accumulated OCI0(149.75K)141K55K334K
Other Stockholders Equity00000
Minority Interest00000
Total Equity106.86M(76.83M)245.91M309.85M459.6M
Total Debt159K323K335K0399K
Net Debt(109.87M)(75.21M)(99.81M)(124.12M)(98.5M)

Balance Sheet

Assets, liabilities & equity

Cash & Equivalents$151.7M
Short-term Investments$732.7M
Other Current$10.4M
Total Current Assets$894.8M
PP&E (Net)$1.5M
Other Non-current$962.0K
Total Non-current Assets$2.5M
Total Assets$897.2M

Analysis

Selected assets total $897.2M for Latest. The largest visible component is Short-term Investments at $732.7M, about 81.7% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 5, 2026
10-QQuarterly reportNov 5, 2026
4Statement of changes in beneficial ownershipNov 3, 2026
SC 13G/ASC 13G/A filingOct 27, 2026
4Statement of changes in beneficial ownershipOct 21, 2026

How much cash does ELVN have?

Enliven Therapeutics, Inc. (ELVN) reported $98.90M in cash and equivalents in fiscal 2025.

How much debt does ELVN carry?

Enliven Therapeutics, Inc. (ELVN) reported $399,000.00 of total debt, with net debt of -$98.50M.